Sanofi
Biosimilar developer, France. 3 development products across 3 molecules: insulin aspart, insulin human, insulin lispro.
About Sanofi
Sanofi is both an originator, with Lantus copied by others, and a biosimilar maker of insulins. Its insulin lispro was the first in Europe, in 2017, its insulin aspart the first in Europe and the first fast-acting insulin biosimilar in the United States, and both are approved in Japan and Canada. In the United States its lispro, Admelog, is a licensed insulin rather than a biosimilar. Its Indian subsidiary Shantha makes human insulin.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Insulin aspart | Merilog / Insulin aspart Sanofi SAR341402 | Feb 2025 | Jun 2020 | MHRA | Mar 2021 | Oct 2020 | May 2023 | · | 6/7 |
| Insulin human | Shantha human insulin | · | · | · | · | · | Nov 2013 | · | 1/7 |
| Insulin lispro | Insulin lispro Sanofi SAR342434 | · | Jul 2017 | MHRA | Mar 2020 | Nov 2017 | · | · | 4/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Sanofi, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCONov 2013Shantha Biotechnics (INN only), insulin human
- EMAJul 2017Insulin lispro Sanofi, insulin lispro
- HCNov 2017Admelog, insulin lispro
- PMDAMar 2020Insulin Lispro BS HU Sanofi, insulin lispro
- EMAJun 2020Insulin aspart Sanofi, insulin aspart
- HCOct 2020Trurapi, insulin aspart
- PMDAMar 2021Insulin Aspart BS NR Sanofi, insulin aspart
- CDSCOMay 2023Sanofi India (INN only), insulin aspart
- FDAFeb 2025Merilog, insulin aspart
Compare Sanofi with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant